VYNE | tickerfilter.com

Fundamental analysis

37%

Profitability 43%

Dept financing 23%

Liquidity 58%

Performance 30%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-0.34%

1 Month

9.12%

3 Months

13.18%

6 Months

78.70%

1 Year

-55.20%

2 Year

-75.47%

Key data

Stock price

$0.65

P/E Ratio

0.00

DAY RANGE

$0.63 - $0.65

EPS

-$0.83

52 WEEK RANGE

$0.28 - $1.96

52 WEEK CHANGE

-$55.20

MARKET CAP

27.497 M

YIELD

N/A

SHARES OUTSTANDING

25.472 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-08-2025

BETA

1.72

PUBLIC FLOAT

AVERAGE 10 VOLUME

$154,991

AVERAGE 30 VOLUME

$115,351

Company detail

CEO: David Domzalski
Region: US
Website: vynetherapeutics.com
Employees: 30
IPO year: 2018

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

VYNE Therapeutics Inc. focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the. treatment of moderate-to-severe acne vulgaris. FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial. for mild to moderate atopic dermatitis, is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor.

VYNE - VYNE Therapeutics Inc.